Mathieu Choufani

@AssafJad Best of luck!!

Excited to be applying to the Ophthalmology match this cycle. As a postdoctoral scholar at the Casey Eye Institute, my work merges corneal imaging, OCT, and clinically useful AI. Looking forward to connect with the community! #OphthoMatch #Match2025

@theliverdoc Thoughts on plant based protein for the ethical vegans?

I think these are the ONLY nutritional supplements worth your time and money (in their recommended situations): - Whey protein isolate - Creatine monohydrate - Black coffee

One interesting finding was that only rheumatology and ophthalmology had positive HLA-B27 rates exceeding the expected U.S. general population prevalence when ordering the test— highlighting opportunities to refine testing and referral practices.

Excited to share our latest publication on HLA-B27 testing in clinical practice, published in The Journal of Rheumatology! pubmed.ncbi.nlm.nih.gov/40451272/

We analyzed how HLA-B27 testing is used by both rheumatologists and non-rheumatologists across a large healthcare system, focusing on testing patterns, co-testing with other autoantibodies, and referral rates to rheumatology.

@williamazar_ @NEJM_AI @NIH @PeterPintoMD @charleshesswani @GuKoller @SahilParikh99 @NeilM15 @apkenigsberg @theNCI @NEJM Great work William !

Excited to share our latest study in @NEJM_AI ! 🚀 We introduce NTEP, a @NIH platform that uses large language models to extract data from unstructured medical reports with 99.8% accuracy – bridging AI with real-world medical research 🔗 Free access: ai.nejm.org/stoken/default…

Our findings underscore the urgent need for multifaceted and intentional recruitment efforts to ensure that clinical trials better represent the populations they aim to serve.

We found: - Reporting of race and ethnicity has generally improved, though many journals only report the % of White participants, often omitting data on other racial and ethnic groups.

Excited to share our latest publication on race, ethnicity, and demographic diversity in pivotal psoriatic arthritis (PsA) clinical trials, conducted under the invaluable mentorship of Joerg Ermann and Niti Goel. acrjournals.onlinelibrary.wiley.com/doi/epdf/10.10…

- Underrepresented racial and ethnic groups face challenges such as transportation issues, childcare obligations, mistrust of the healthcare system, provider biases, and other systemic barriers (e.g. poor infrastructure). Our manuscript explores some strategies to address these.

- Pivotal PsA trials are mostly in North America and Western Europe, with limited representation from Asia, Africa, and Latin America. Recent trial site increases in Eastern Europe and East/Southeast Asia haven't significantly diversified trial populations.

- Although many PsA trial sites were concentrated in racially and ethnically diverse states like California, Texas, and Florida, this diversity was not reflected in the trial populations. Simply having trial sites in diverse states does not guarantee diverse enrollment.

- Racial and ethnic diversity in pivotal PsA trials remains limited, with 92% of participants being White. Notably, this figure has shown little to no change from 2000 to 2020.

@Wissam_Ghusn @dr_aac @OMGhanemMD Fantastic work Wissam!

Enjoyed a productive and inspiring #DDW2025! Grateful to my mentors for their guidance and for creating opportunities to keep learning and growing in the field of GI @dr_aac @OMGhanemMD

@Wissam_Ghusn Great work!!

Excited to serve as the Guest Editor for our new Special Issue at Biomedicine! We're exploring how bariatric procedures (Endoscopic and Surgical) and anti-obesity medications reshape Obesity-Related GI Disorders: MASLD, GERD, IBD & others. For more info: mdpi.com/journal/biomed…

@Wissam_Ghusn @Spondy_MD @JoergErmann @SPARTAN_Updates Diversity in axSpA drug trials is improving, but we still have a long way to go. Greater inclusion by race, ethnicity, gender, and geography is important to ensure trial findings are more applicable to the patients we see in our clinics.

Excited to share our new publication on demographic & geographic diversity in axial spondyloarthritis drug trials! We analyzed 59 trials (16,000+ participants) since 2000. Big thanks to the team @Wissam_Ghusn @Spondy_MD @JoergErmann @SPARTAN_Updates! pubmed.ncbi.nlm.nih.gov/40089303/

@Wissam_Ghusn @Spondy_MD @JoergErmann @SPARTAN_Updates - 53 countries enrolled patients, but very few trials in many regions including Sub-Saharan Africa, South/Central Asia, Latin America and the MENA. - 92% of trials conducted in high-income countries - Only 2 trials conducted in low or low-middle income countries.

@Wissam_Ghusn @Spondy_MD @JoergErmann @SPARTAN_Updates - Black patients made up just 1% of trial participants. - Only 1 Native Hawaiian/Pacific Islander ever recruited in an AxSpA drug trial! - Representation of Asian, American Indian/Alaska Native, and Hispanic/Latino participants improved (progress, but not enough).

@Wissam_Ghusn @Spondy_MD @JoergErmann @SPARTAN_Updates Key findings from our axSpA trial diversity study: — Female enrollment largely reflects disease prevalence (25% in AS, 48% in nr-axSpA) — Trials reporting participant race rose from 9% (early 2000s) to 100% (~2020). — Participant ethnicity reporting still lagging behind